Examining the bacterial diversity including extracellular vesicles in air and soil: implications for human health

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0320916 - e0320916

Published: April 1, 2025

As the significance of human health continues to rise, microbiome has shifted its focus from microbial composition functional roles it plays. In parallel, interest in ultrafine particles associated with clinically important impact been increasing. Bacterial extracellular vesicles (BEVs), involved systemic activity, are nano-sized spherical (20 - 100 nm diameter) containing DNA, RNA, proteins, and lipids. They known be absorbed into body potentially through air soil, circulate blood, directly diseases by affecting organs. Therefore, aim this study is examine biodiversity bacteria BEVs predicted pathways. We sampled soil samples Seoul, Korea analyzed metagenomics based on 16S rRNA sequencing. At phylum levels, Firmicutes were significantly higher than bacteria, Acidobacteria both (p < 0.05). The most dominant genera Pseudomonas soil; Escherichia–Shigella soil. addition, Two-component system (ko02020) ATP-binding cassette transporters (ko02010) pathways orthologous groups different between conclusion, can affected differently depending type environment. Future necessary have a better understanding effects environmental microbiota.

Language: Английский

Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 16, 2025

The PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case sintilimab-induced dermatomyositis in patient with gastric cancer and liver metastasis to raise awareness this serious adverse event. A 64-year-old man presented onset received two cycles plus nab-paclitaxel. experienced fever, thrombocytopenia, rash during first-cycle treatment, followed by bilateral ptosis, dysphagia, slurred speech, myalgia second-cycle treatment. Elevated muscle enzymes, electromyography, positive myositis antibodies confirmed diagnosis dermatomyositis. He was treated high-dose corticosteroids immunoglobulin, resulting symptom improvement. This widens spectrum immune-related toxicity associated sintilimab, as well highlights need early recognition management these events patients receiving ICIs.

Language: Английский

Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

The discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, comprehensive analysis the potential adverse effects ICIs SCLC remains to be conducted.

Language: Английский